“This is the perfect technique to identify high-risk patients who would benefit from intensive therapies,” imaging specialist Gudrun Feuchtner, MD, told Cardiovascular Business.
According to new projections, the nearly 100 million CT scans conducted in the U.S. during 2023 will result in approximately 103,000 future cancer diagnoses annually due to radiation exposure alone.
Currently there are no FDA cleared echocardiography contrast agents commercially available for use on the right side of the heart to detect shunts, but a new agent that promises to improve workflow and imaging is about to enter a U.S. trial.
